Emergence of in vitro resistance to lenacapavir is similar across HIV-1 subtypes
In-vitro susceptibility to LEN was not affected by the subtype of the samples tested, and selected resistance mutations were not significantly different across HIV-1 subtypes. These data indicate that LEN is a pan-genotypic inhibitor of HIV-1 that can be effective in all geographical settings, regardless of HIV-1 subtypes.
Authors
- Brie Falkard (ORCID: https://orcid.org/0009-0006-8599-8173)
- Vidula Naik
- Archana V. Boopathy (ORCID: https://orcid.org/0009-0009-9164-0858)
- Nicolas Margot (ORCID: https://orcid.org/0000-0002-0911-4237)
- Anurag Nekkalapudi
- Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)
Institutions
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- AIDS
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1097/qad.0000000000004334
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00